Nusinersen is named as an intervention in 3 current clinical trials in our USA and UK registers. 2 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Biogen (2). The most-studied condition is Spinal Muscular Atrophy.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
NCT07047144 · ClinicalTrials.gov ↗ · Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2
|
Phase 2 | Recruiting | Scholar Rock, Inc. | UK, USA |
|
A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)
NCT06555419 · ClinicalTrials.gov ↗ · Muscular Atrophy, Spinal
|
Phase 1 | Recruiting | Biogen | UK, USA |
|
A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)
NCT05067790 · ClinicalTrials.gov ↗ · Spinal Muscular Atrophy
|
Phase 3 | Active, closed | Biogen | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
3 single-substance products containing Nusinersen on the HPRA medicines list.
No entry for Nusinersen in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| Biogen | 2 |
| Scholar Rock, Inc. | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 3 | 2 |
| Clinical trials in UK | 2 | 2 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our USA and UK registers name Nusinersen as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 2 with sites in USA and 2 with sites in UK. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Biogen (2) and Scholar Rock, Inc (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 3 single-substance products containing Nusinersen, for example Spinraza 12 mg solution for injection (Biogen Netherlands B.V.). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Nusinersen has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Nusinersen works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Nusinersen works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Nusinersen (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.